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Charles T. Klodell, and W. Anthony Lee, From the University of Florida.
Gainesville, Fla
Background: Thoracic endovascular aortic repair (TEVAR) is a mini-
mally invasive alternative to open repair of many thoracic aortic pathologies.
Most of the published data to date involve a relatively limited number of
individuals and follow-up. In this descriptive study, we report our midterm
outcomes of a large, decade-long, single-center TEVAR experience.
Methods: A prospectively maintained TEVAR registry and electronic
medical records at a tertiary care center were retrospectively analyzed for
patient characteristics, intraoperative details, and early and late postoperative
outcomes.
Results: From 2000 to 2009, 400 consecutive TEVARs were per-
formed using seven endograft systems (TAG, 65%; TX2, 18%; Talent, 6%;
aortic cuff, 3%; and investigational, 8%). More than 91% were performed in
the last 5 years of the study. The distribution of pathologies treated included
198 aneurysms (50%), 100 dissections (25%), 54 penetrating ulcers (13%),
25 traumatic transections (6%), and 23 other pathologies (6%). Dissections
represented the single fastest growing segment being treated. Men com-
prised 69%, the mean age was 65  16 years, and 18% had had prior
abdominal aortic replacements. Thirty-two percent of cases were performed
urgently or emergently. Sixty-nine percent were American Society of Anes-
thesiology class IV, and 61% underwent general anesthesia. Spinal drains
were prophylactically placed in 127 cases (32%) of planned extended aortic
coverage. There were no acute surgical conversions. Mean number of
devices was 2.3  1.1, and 63% of cases were completed with one or two
devices. Mean fluoroscopy was 24  15 minutes, contrast was 139  54
mL, blood loss was 309  316 mL, and procedure time was 116  5
minutes. Sixteen percent required iliac conduits. Fifty-one percent of prox-
imal landing zones involved zones 0 to 2. Preoperative adjunctive surgical
procedures were performed on 94 patients (24%). These included arch
debranching in 22 (6%), first-stage elephant trunk in 20 (5%), visceral
debranching in 21 (5%), and left subclavian revascularization in 31 (8%).
Subclavian revascularizations were selectively performed in only 17% of zone
2 deployments. The median length of stay was 5 days (range, 1-79 days).
Incidence of type I/III endoleak was 10% and 5% at 1 and 12 months,
respectively. Overall 30-day mortality was 6.5% (elective, 2.6%; urgent,
9.5%; emergent, 20%). Permanent spinal cord ischemia occurred in 3.6% and
stroke in 2.1%. Kaplan-Meier estimates of survival were 81%, 76%, and 69%,
and freedom from secondary intervention were 90%, 86%, and 82% at 6, 12,
and 24 months, respectively.
Conclusions: Since commercial availability of thoracic endografts,
TEVAR has been used to treat a variety of thoracic aortic pathologies, many
of which were off-label.With careful planning and technique, the procedures
can be performed with virtually zero risk of intraoperative conversion.
Although overall rates of mortality and neurologic complications were
relatively low, they were significantly increased in emergency repairs. There
appears to be substantial number of late deaths that may represent a
combination of poor patient selection or treatment failures.
Preoperative Thrombolysis and Venoplasty Affords no Benefit in Pa-
tency Following First Rib Resection and Scalenectomy for Subclavian
Vein Thrombosis
James L. Guzzo, Kevin Chang, Jasmine Demos, James H. Black III, and
Julie A. Freischlag, From The Johns Hopkins Hospital. Balitmore, Md
Background: Subclavian vein thrombosis is a rare presentation of
thoracic outlet syndrome (TOS). Typical treatment patterns consist of
preoperative anticoagulation, followed by operative decompression by first
rib resection and scalenectomy (FRRS). Recently, thrombolytic therapy has
been used as the initial treatment with anticoagulation and FRRS. This study
reviewed our extensive experience and compared the effectiveness of preop-
erative thrombolysis and venoplasty with anticoagulation alone in those
undergoing FRRS to preserve subclavian vein patency.
Methods: A retrospective review was conducted for all venous TOS
patients from July 2003 to May 2009 from a prospectively maintained
database. Patient demographics and use of preoperative anticoagulation,
thrombolysis, and percutaneous venoplasty were recorded. Reports of fol-
low-up venograms after FRRS were analyzed with regard to axillosubclavian
vein patency, percutaneous venoplasty, results of intervention, and presence
of occlusions. Postoperative clinic evaluations and duplex imaging reports
were reviewed for presence of symptoms, recanalization, chronic nonocclu-
sive thrombus, or continued complete occlusion.
Results: A total of 103 patients (53 men, 50 women) had 110 FRRSs
for subclavian vein thrombosis, seven of which had contralateral FRRS for
thrombosis. The average age was 31 years (range, 16-54 years), with a mean
follow-up of 13 months (range, 1-52 months). Overall before FRRS, 65
patients (59%) were managed with anticoagulation alone and 45 (41%) had
preoperative endovascular interventions. Of these 45 patients, 22 (49%)
underwent thrombolysis alone and 23 (51%) underwent thrombolysis andaxillosubclavian balloon venoplasty. After FRRS, 43 patients (96%) had
follow-up venograms 2 weeks postoperatively revealing patent subclavian
veins in 15 patients, stenosis requiring balloon dilatation in 21, and occlu-
sions in seven (16%). The overall initial patency rate in this group was 84%.
In follow-up, recanalization was documented in five of the seven occlusions,
with restoration of the patency of the subclavian vein at a mean of 2.8
months postoperatively (range, 1-6 months). In the 65 patients managed
with anticoagulation alone before FRRS, 61 (94%) underwent follow-up
venograms. The venograms revealed patent subclavian veins in 15 patients,
stenosis requiring balloon dilatation in 36, and 10 occlusions (16%). Eight of
10 occlusions were recanalized at an average of 4.3 months (range, 1-11
months) after FRRS.
Conclusions: Although initial treatment strategies for subclavian vein
thrombosis may differ, a combination of anticoagulation, thrombolysis,
operative decompression with FRRS, and postoperative endovascular inter-
ventions can yield excellent outcomes. A large proportion of patients in this
series (41%) underwent thrombolysis before operative decompression with
FRRS but showed no improvement in outcome as determined by vein
patency on postoperative venography and duplex imaging during follow-up.
Our large series suggests preoperative treatment with anticoagulation alone
has vein patency rates similar to patients undergoing thrombolytic therapy.
This treatment paradigm also has tremendous cost containment potential
given the use of outpatient anticoagulation at the initial presentation has an
obvious lower cost than an inpatient endovascular intervention. Overall, 106
of 110 of our patients (96%) had patent subclavian veins during our
follow-up interval, were asymptomatic, and back to their previous active
lifestyle.
Type B Thoracic Aortic Dissection: Open vs Endovascular Repair
Teviah Sachs, Robert Hagberg, Frank Pomposelli, Allen Hamdan, Mark
Wyers, Kristina Giles, and Marc Schermerhorn, From Beth Israel Deaconess
Medical Center. Boston, Mass
Background: This study assessed morbidity and mortality in patients
with type B thoracic aortic dissection (TADB) who undergo operative repair.
Methods: We queried the Nationwide Inpatient Sample (NIS) data-
base, examining all records between 2005 and 2007. Using International
Classification of Diseases (9th ed) diagnosis codes, we selected patients who
underwent an open repair or an endovascular stent graft repair for a diagno-
sis of TAD. We isolated only those patients undergoing repair for TADB by
excluding patients with diagnosis codes for aortic aneurysm and procedure
codes for cardioplegia or for operations on vessels of the heart or valves. We
compared demographics and comorbidities, as well as adjusted complica-
tions and mortality between the cohorts.
Table I. Demographics and comorbidities for
endovascular stent graft vs open repair
Variable Total
Endovascular Open repair
PNo. Yrs or % No. Yrs or %
Average age 8883 1427 62.2 yrs 7456 59.8yrs .065
Female 8883 503 35 2283 31 .168
Prior myocardial infarction 3334 45 6 87 3 .114
Chronic pulmonary disorders 3334 161 22 454 17 .206
Diabetes 3334 90 12 163 6 .063
Hypertension 3334 533 73 1517 58 .015
Neurologic disorders or paralysis 3334 24 3 201 8 .067
Peripheral vascular disease 3334 295 40 646 25 .005
Renal failure 3334 95 13 274 11 .367
Table II. Outcomes for endovascular stent graft vs open
repair
Outcome Total
Endo
(n  1427)
Open
(n  7456)
OR (95% CI) PNo. (%) No. (%)
Death 318 145 (10) 1416 (19) 2.25 (1.32-3.81) .001
LOS median 9.63
days
4652 605 (42) 4047 (54) 1.67 (1.14-2.44) .009
Hemorrhage 1061 39 (3) 1022 (14) 5.45 (2.38-12.51) .0001
Cardiac complication 1160 82 (6) 1077 (14) 2.22 (1.31-3.79) .004
Genitourinary
complication
528 29 (2) 499 (7) 3.27 (1.15-9.29) .025
Stroke 418 36 (3) 381 (5) 1.6 (0.61-4.19) .39
Peripheral vascular
complication
121 25 (2) 96 (1) 1.23 (0.18-8.31) .85CI, Confidence interval; LOS, length of stay. OR, odds ratio.
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open (84%) and 1427 endovascular (16%; Table I). Of these, 49 patients
were converted from endovascular to open. Patients in the endovascular
group were older with greater comorbidities, although only hypertension
and peripheral vascular disease were statistically significant. In hospital
mortality was 18.9% for open repair vs 10.1% for endovascular repair (Table
II) with an odds ratio of 2.25 (95% confidence interval, 1.32-3.81; P .01).
Cardiac complications (14% vs 6 %, P  .01), genitourinary complications
(7% vs 2%, P  .05), and hemorrhage (14% vs 3%, P  .01) were all more
frequent in the open repair group. The median in-hospital length of stay was
also greater in the open repair group (10.05 vs 7.8 days, P  .01).
Conclusions: For patients with a diagnosis of TADB who undergo
repair, the endovascular approach is being used for, on average, older
patients with greater comorbidities yet has reduced morbidity and mortality.
Staged Total Exclusion of the Aorta for Chronic Type B Aortic
Dissection: A Case Report
Anton Dias Perera, Alan Willis, Joss D. Fernandez, H. Edward Garrett Jr,
and Bradley A. Wolf, From the University of Tennessee. Memphis, Tenn
Background: Hybrid techniques for repair of extensive thoracoab-
dominal aneurysms have been previously described. Variable lengths of the
thoracic and abdominal aorta have been excluded or replaced using these
techniques with good outcomes. The most feared complication of this
approach is spinal cord ischemia, as intercostal arteries are not reimplanted.
We describe a five-stage endograft repair of a complex, chronic Stanford type
B aortic dissection.
Case report: A 50-year-old man with a history of a chronic type B
aortic dissection developed aneurysmal dilatation of the proximal descend-
ing thoracic aorta (maximum diameter, 7 cm). The dissection extended into
both iliac arteries. The celiac trunk, superior mesenteric artery, and left renal
artery were perfused by the false lumen. The infrarenal abdominal aorta
measured 5.3 cm. He was treated initially with a proximal thoracic endograft
and carotid-subclavian bypass. A type IA endoleak required proximal exten-
sion with exclusion of the aortic arch and ascending aorta-innominate and
left carotid bypass. An abdominal endograft was deployed simultaneously to
compress the false lumen in the aneurysmal infrarenal aorta. An endoleak in
the left iliac limb and progression of the dissection in the right internal iliac
artery required bilateral iliac limb extensions. A surveillance computed
tomography (CT) angiogram revealed persistent perfusion of the false
lumen through perivisceral fenestrations. All therapeutic options were re-
evaluated, including medical management, and a hybrid procedure was
performed to exclude the descending and perivisceral aorta. Mesenteric and
bilateral renal bypass grafts originating from the external iliac artery were
performed, followed by endografting of the remaining descending thoracic
and abdominal aorta (Fig). Spinal cord protective measures, including spinal
Fig 1. Reconstructed computed tomography imaging shows the
entire native aorta and iliac arteries to the external iliac branches
have been excluded with endografts.fluid drainage and lower extremity motor-evoked potential monitoring,
were used during the case. The patient did not have any neurologic sequelae
and made an excellent postoperative recovery. A subsequent CT angiogram
confirmed thrombosis of the false lumen with no endoleak.
Conclusion: Chronic aortic dissection with aneurysmal enlargement
results in complex aortic pathology.Hemodynamic changes that occur when
the aorta is excluded in segments are sometimes unpredictable due to
multiple fenestrations throughout the dissected aorta. In this case, the aorta
was excluded from the ascending arch to both external iliac arteries using
endografts, without spinal cord complication. The aortic arch branches,
visceral, and renal arteries were bypassed using this hybrid technique. To our
knowledge, this is the first reported case in which the entire native aorta and
iliac arteries to the external iliac branches were excluded with endografts.
This case report illustrates the feasibility of the hybrid technique in selected
patients when confronted with complex aortic pathology.
Table. Procedures performed
Stage Procedure Device(s) Time (d)
1 Left carotid-subclavian
bypass and thoracic
endograft of
proximal descending
aortic aneurysm
6-mm ePTFE bypass graft;
Medtronic Talent 46 
46  110-mm proximal
main body and 46  44
 110-mm distal main
body
0
2 (a) Proximal extension
of the thoracic
endograft with
exclusion of the
aortic arch and
ascending aorta-
innominate and left
carotid bypass; (b)
repair of infrarenal
abdominal aortic
dissection and
aneurysmal dilatation
with modular
bifurcated aortic
stent graft with one
docking limb
(a) Bifurcated bypass graft
(10  8 mm) from
ascending aorta to
innominate and left
carotid arteries; proximal
thoracic extension main
body (46  46  110
mm); (b) Medtronic
AneuRx endograft (24 
135 mm) with one
docking limb
3
3 (a) Repair of type IB
endoleak with
extension graft to
left external iliac
artery; (b) balloon
angioplasty of distal
landing zone of
TEVAR
Medtronic AneuRx iliac
limb extension (16 
135 mm)
55
4 (a) Repair of right
internal iliac artery
dissection and
aneurysmal dilatation
with limb extension
of EVAR to right
external iliac artery;
(b) distal extension
cuff to TEVAR to
seal type IB endoleak
(a) AneuRx iliac limb
extension (16  115
mm); (b) distal thoracic
main body extension
(Medtronic Talent 46 
46  110 mm
59
5 Mesenteric and
bilateral renal bypass
from the external
iliac artery and
endografting of
descending thoracic
and perivisceral aorta
12  6-mm and 14  7-
mm bifurcated ePTFE
grafts); distal thoracic
extension (Medtronic
Talent 40  36  110
mm and 42  38  110
mm) proximal
abdominal extension
(Talent 40  36  110
mm)
99
EVAR, Endovascular aneurysm repair; ePTFE, expanded polytetrafluoro-
ethylene; TEVAR, thoracic endovascular aortic repair.
Revascularization of the Left Subclavian Artery during TEVARUtiliz-
ing a Percutaneous In-Situ Technique
Frank R. Arko III, Taylor A. Smith, and J. Michael Dimaio, From the
University of Texas Southwestern Medical Center. Dallas, Tex
